Adrian Rawcliffe, CEO of Adaptimmune and former finance executive, shares his insights on the groundbreaking FDA approval of the first TCR cell therapy for synovial sarcoma. He discusses the dynamic shift from traditional therapies to innovative cell-based treatments and the unique challenges this poses in manufacturing and logistics. Rawcliffe emphasizes the importance of blending financial expertise with scientific innovation. He also highlights the future of T-cell therapies and the industry's push towards generics and biosimilars, paving the way for enhanced patient access.